江苏联环药业股份有限公司关于控股股东股权结构变动的提示性公告

Core Viewpoint - The announcement details a change in the equity structure of Jiangsu Lianhuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Lianhuan Pharmaceutical") due to the transfer of state-owned shares from the controlling shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Lianhuan Group"), to the Jiangsu Provincial Department of Finance, which will not affect the company's operational control or shareholding structure [2][3]. Summary of Key Points 1. Change in Controlling Shareholder's Equity Structure - The Jiangsu Provincial State-owned Assets Supervision and Administration Commission (hereinafter referred to as "Yangzhou SASAC") transferred 10% of its shares in Lianhuan Group and 6.45% of its shares in Yangzhou Industrial Investment Development Group Co., Ltd. (hereinafter referred to as "Investment Group") to the Jiangsu Provincial Department of Finance without compensation [2][4]. - This transfer will not change the number of shares or the proportion of shares held by Lianhuan Group in Lianhuan Pharmaceutical [2][3]. 2. Regulatory Compliance - According to the relevant provisions of the "Measures for the Administration of Takeovers of Listed Companies," this transfer does not trigger a mandatory tender offer [3][4]. 3. Impact on Company Operations - The equity structure change will not alter the controlling shareholder or actual controller of the company, and it will not have a substantial impact on the company's daily operations and production activities [3][9]. - After the transfer, the Jiangsu Provincial Department of Finance will indirectly hold 4.968% of Lianhuan Pharmaceutical's shares through Lianhuan Group and Investment Group [5][7]. 4. Future Developments - As of the announcement date, the relevant industrial and commercial change registration procedures for Lianhuan Group have been completed, while those for Investment Group are still in progress [9].